Fundraising Fox
/Companies
Sign in

TuHURA Biosciences Inc./NV

NASDAQ: HURA

Tampa, US · Nevada corporation

Find your way into TuHURA Biosciences Inc./NV

Sign up to see every warm intro you have to TuHURA Biosciences Inc./NV

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the TuHURA Biosciences Inc./NV team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Túhura Biosciences is a clinical-stage biopharmaceutical company developing immuno-oncology therapies, including innate immune agonists and bi-specific immune-modulating antibody drug conjugates (ADCs). Its pipeline includes IMMUNE FX (IFX) and TBS-2025, with a Phase 3 registration trial underway.

BiotechMedical Devices

Founders & leadership

DB
Dennis BrownOfficer/Director
DDDan Dearborn
Dan DearbornExecutive
JBJames Bianco
James BiancoExecutiveDr. James Bianco holds an M.D. from Mount Sinai Icahn School of Medicine and completed fellowship training in hematology/oncology at the University of Washington and Fred Hutchinson Cancer Research Center. He is President and CEO of TuHURA Biosciences, a clinical-stage immuno-oncology company, and previously founded and led CTI Biopharma, where he contributed to the development of multiple FDA/EMA-approved therapies and oversaw the acquisition by SOBI for $1.75B.
SP
Scott PraillOfficer
JB
Jeffrey BachaNamed on SEC filing

Board

JM
James ManusoBoard director
AL
Alan ListBoard director
CT
Craig TendlerBoard director
RH
Robert HoffmanBoard director
GN
George NgBoard director
JK
John K BellBoard director
RT
Robert TothBoard director

Reported raises · per SEC filings

Form D private placements

$52.9M disclosed across 5 rounds · 2016–2025

▶$1.5MraisedNov 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan ListDirector
  • Craig TendlerDirector
  • George NgDirector
  • Robert HoffmanDirector
  • James BiancoExecutive Officer, Director
  • James ManusoDirector
  • Dan DearbornExecutive Officer
Offering amount
$3M
Amount sold
$1.5M
First sale
Oct 2025
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedJun 2025 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James ManusoDirector
  • Alan ListDirector
  • Craig TendlerDirector
  • Dan DearbornExecutive Officer
  • James BiancoExecutive Officer, Director
  • Robert HoffmanDirector
  • George NgDirector
Offering amount
$12.6M
Amount sold
$2.2M
Sales commissions
$948.1K
Placement agents
Paulson Investment Company, LLC, Brookline Capital Markets, a division of Arcadia Securities, LLC
First sale
Jun 2025
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.8MraisedAug 2020 · 161 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert HoffmanDirector
  • Scott PraillExecutive Officer
  • Laura JohnsonDirector
  • Dennis BrownExecutive Officer
  • Saiid ZarrabianExecutive Officer, Director
  • Keith MurphyDirector
  • Steven RychnovskyExecutive Officer
  • John LiatosExecutive Officer, Director
  • Robert TothDirector
Offering amount
$30M
Amount sold
$21.8M
Sales commissions
$3M
Placement agents
Aegis Capital Corp.
First sale
Aug 2020
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.8MraisedAug 2020 · 161 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Saiid ZarrabianExecutive Officer, Director
  • Laura JohnsonDirector
  • John LiatosExecutive Officer, Director
  • Keith MurphyDirector
  • Scott PraillExecutive Officer
  • Robert HoffmanDirector
  • Dennis BrownExecutive Officer
  • Steven RychnovskyExecutive Officer
  • Robert TothDirector
Offering amount
$30M
Amount sold
$21.8M
Sales commissions
$3M
Placement agents
Aegis Capital Corp.
First sale
Aug 2020
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.6MraisedMay 2016 · 85 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John K BellDirector
  • Robert TothDirector
  • Lynda CranstonDirector
  • Erich MohrDirector
  • Dennis BrownExecutive Officer, Director
  • Scott PraillExecutive Officer
  • Jeffrey BachaExecutive Officer, Director
Amount sold
$5.6M
Sales commissions
$110.5K
Finders' fees
$120.1K
Proceeds to insiders
$1.7M
Placement agents
Aegis Capital Corp, Newport Coast Scurities Inc
First sale
Apr 2016
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$10.5Mvaluation at IPOAug 2019 · $0.99/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does TuHURA Biosciences Inc./NV do?
Túhura Biosciences is a clinical-stage biopharmaceutical company developing immuno-oncology therapies, including innate immune agonists and bi-specific immune-modulating antibody drug conjugates (ADCs). Its pipeline includes IMMUNE FX (IFX) and TBS-2025, with a Phase 3 registration trial underway.
Who founded TuHURA Biosciences Inc./NV?
TuHURA Biosciences Inc./NV was founded by Dennis Brown.
How much funding has TuHURA Biosciences Inc./NV raised?
TuHURA Biosciences Inc./NV has disclosed $52.9M raised across 5 rounds.
Where is TuHURA Biosciences Inc./NV headquartered?
TuHURA Biosciences Inc./NV is headquartered in Tampa, US.